Clinical aspects of previously treated chromoblastomycosis: A case series from Madagascar

Int J Infect Dis. 2020 Dec:101:228-232. doi: 10.1016/j.ijid.2020.09.1479. Epub 2020 Oct 2.

Abstract

Objective: To describe the clinical aspects of chromoblastomycosis (CBM) presented by patients who had received incomplete antifungal treatment before consultation.

Methods: A prospective study of patients with clinically suspected CBM was performed between 2013 and 2018 in the Department of Dermatology at the University Hospital Antananarivo, and during consultation campaigns.

Results: Patients develop CBM over a period of more than 10 years, and many will have already received antifungals prescribed by general practitioners before consulting with a dermatologist. Such treatment obviously modifies the clinical presentation. From the 63 CBM patients in this large study, we describe 12 patients who received oral antifungals (terbinafine, griseofulvine, itraconazole, fluconazole) before consultation. The most frequent clinical aspect presented by these patients was cicatricial lesions, which are characteristically smooth and non-elevated, and enlarge by peripheral extension, with atrophic scarring at the center.

Conclusion: Our study is the first to show that cicatricial lesions are a clinical aspect presented by CBM patients who received antifungals before presentation.

Keywords: Chromoblastomycosis; Cicatricial lesion; Madagascar.

MeSH terms

  • Adult
  • Aged
  • Antifungal Agents / therapeutic use*
  • Chromoblastomycosis / drug therapy*
  • Chromoblastomycosis / microbiology
  • Chromoblastomycosis / pathology
  • Female
  • Humans
  • Itraconazole / therapeutic use
  • Madagascar
  • Male
  • Middle Aged
  • Prospective Studies
  • Terbinafine / therapeutic use

Substances

  • Antifungal Agents
  • Itraconazole
  • Terbinafine